Search

Your search keyword '"Rifabutin pharmacology"' showing total 412 results

Search Constraints

Start Over You searched for: Descriptor "Rifabutin pharmacology" Remove constraint Descriptor: "Rifabutin pharmacology"
412 results on '"Rifabutin pharmacology"'

Search Results

1. Determination of bactericidal activity against 3HC-2-Tre-labelled Mycobacterium abscessus (Mycobacteroides abscessus) by automated fluorescence microscopy.

2. PKC-α is involved in the signaling of phagocytosis induced by two snake venom secretory PLA 2 S in macrophages.

3. Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.

4. Efficacy of rifapentine and other rifamycins against Coxiella burnetii in vitro .

5. Genome-Driven Discovery of Hygrocins in Streptomyces rapamycinicus .

6. Antibiotic Adjuvant 4-Hexylresorcinol Enhances the Efficiency of Antituberculosis Drugs.

7. Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan.

8. Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site.

9. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].

10. ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate.

11. In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus.

12. CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus.

13. Structure-activity relationships of actively FhuE transported rifabutin derivatives with potent activity against Acinetobacter baumannii.

14. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus , Mycobacterium chelonae , and Mycobacterium fortuitum in BALB/c mice models.

15. The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori.

16. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.

17. Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria.

18. Structural diversity and biological relevance of benzenoid and atypical ansamycins and their congeners.

19. Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report.

20. Mycobacterium abscessus HelR interacts with RNA polymerase to confer intrinsic rifamycin resistance.

21. Differential Impact of the rpoB Mutant on Rifampin and Rifabutin Resistance Signatures of Mycobacterium tuberculosis Is Revealed Using a Whole-Genome Sequencing Assay.

22. Arabinosyltransferase C Mediates Multiple Drugs Intrinsic Resistance by Altering Cell Envelope Permeability in Mycobacterium abscessus.

23. A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis.

24. Design and synthesis of water-soluble prodrugs of rifabutin for intraveneous administration.

25. In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.

26. Low-Dose Rifabutin Increases Cytotoxicity in Antimitotic-Drug-Treated Resistant Cancer Cells by Exhibiting Strong P-gp-Inhibitory Activity.

27. In vitro activity of rifabutin against Mycobacterium abscessus, clinical isolates.

28. Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections.

29. Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea.

30. In Vitro Activity of Rifabutin and Rifampin against Antibiotic-Resistant Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae.

31. Genetic Determinants of Intrinsic Antibiotic Tolerance in Mycobacterium avium.

32. MIC Distributions of Routinely Tested Antimicrobials and of Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline for Mycobacterium fortuitum.

33. In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection.

34. In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex.

35. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.

36. Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.

37. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.

38. Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.

39. Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the rpoB gene of Mycobacterium tuberculosis clinical isolates in Shanghai, PR China.

40. Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.

41. Rifabutin Is Inactivated by Mycobacterium abscessus Arr.

42. Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus.

43. Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis.

44. MIC Ranges of Quality Control Strain Mycobacterium peregrinum ATCC 700686 against Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline.

45. In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.

46. Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms.

47. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.

48. Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.

49. A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii.

50. Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin.

Catalog

Books, media, physical & digital resources